Chevy Chase Trust Holdings LLC Sells 4,394 Shares of Hologic, Inc. (NASDAQ:HOLX)

Chevy Chase Trust Holdings LLC lowered its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 178,955 shares of the medical equipment provider's stock after selling 4,394 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.08% of Hologic worth $11,054,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. Smithfield Trust Co grew its position in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Raiffeisen Bank International AG bought a new position in Hologic during the 4th quarter worth approximately $49,000. Finally, West Financial Advisors LLC purchased a new position in Hologic in the 1st quarter worth approximately $50,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Up 0.2%

Hologic stock traded up $0.15 during trading hours on Monday, hitting $65.16. 1,590,544 shares of the stock traded hands, compared to its average volume of 2,366,784. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The firm's 50-day moving average price is $60.17 and its two-hundred day moving average price is $63.84. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. The company has a market cap of $14.52 billion, a PE ratio of 27.49, a PEG ratio of 2.38 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. On average, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Royal Bank Of Canada decreased their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Finally, Evercore ISI dropped their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and an average price target of $77.42.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director directly owned 5,445 shares in the company, valued at $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.